000 01003 a2200253 4500
005 20250515134013.0
264 0 _c20090106
008 200901s 0 0 eng d
022 _a0738-081X
024 7 _a10.1016/j.clindermatol.2007.10.027
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSchön, Michael P
245 0 0 _aEfalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety.
_h[electronic resource]
260 _bClinics in dermatology
_c
300 _a509-14 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650 0 4 _aAntibodies, Monoclonal
_xadverse effects
650 0 4 _aAntibodies, Monoclonal, Humanized
650 0 4 _aCD11a Antigen
_ximmunology
650 0 4 _aHumans
650 0 4 _aPsoriasis
_xdrug therapy
773 0 _tClinics in dermatology
_gvol. 26
_gno. 5
_gp. 509-14
856 4 0 _uhttps://doi.org/10.1016/j.clindermatol.2007.10.027
_zAvailable from publisher's website
999 _c18226025
_d18226025